Skip To Main Content
Daniel Alcalá-López on Muck Rack

Daniel Alcalá-López

As seen in: Nature, ONCOLOGY journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Daniel Alcalá-López’s profile

Articles by Daniel Alcalá-López

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

|
By Jose Perez-Garcia, Javier Cortés, Manuel Ruiz-Borrego, Agostina Stradella, Begoña Bermejo, Santiago Escrivá-de-Romaní, Vega Iranzo, Nuria Ribelles, Florence Dalenc, Aleix Prat, Peter Schmid, Geraldine Gebhart, Frederik Marmé, Serena Di Cosimo, Sofia Braga, Marco Colleoni, Gabriele Antonarelli, Giulia Notini, Maria Gion, Lucía Sanz Verified, Elena Martinez-Garcia, Derek Dustin, Ana Amaya-Garrido, Daniel Alcalá-López, Jose Rodríguez-Morató, Leonardo Mina, Antonio Llombart-Cussac, Cristina Reboredo, Cinta Albacar, Noelia Martínez-Jáñez, Juan José García-Mosquera, Alba Meya, Jose Antonio Guerrero-Martínez, Mario Mancino
| Nature Verified
Abstract PHERGain was a randomized, non-comparative phase 2 trial evaluating a positron 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET)-guided, pathological complete response (pCR)-adapted strategy to omit chemotherapy in HER2-positive early breast cancer. Female patients with HER2-positive stages I–IIIA operable breast cancer (tumor size ≥ 1.5 cm) were randomized to receive chemotherapy plus trastuzumab and pertuzumab (HP; group A) or HP ± endocrine therapy (group B).
Open in Who Shared Issue with article?

Artificial intelligence for clinical data extraction from EHRs in breast cancer trials: the MIRROR study

|
By Carlos Luis Parra-Calderón, Manuel Ruiz-Borrego, Joan García Verified, Carlos Dominguez Verified, Carlos Domínguez Verified, CRISTINA FERNÁNDEZ, Cristina Fernandez Verified, Sara González-García, Carlos Jiménez-Cortegana, Daniel Alcalá-López, Miguel Sampayo-Cordero, Jose Perez-Garcia, Antonio Llombart-Cussac, Javier Cortés, María Campos, Leonardo Mina, Joan Guich, Marta Martínez de Falcón, Alicia García-Sanz
| Nature Verified
Abstract Manual data entry and curation is the most used method of data collection for real world evidence and clinical trials but is a time-consuming task associated with significant human effort and transcription mistakes. MIRROR is a retrospective study that compared manual data capture from electronic case report forms (eCRF) to automated data extraction from electronic health records (EHRs) using artificial intelligence (AI).
Open in Who Shared Issue with article?

Daniel Alcalá-López

|
By Daniel Alcalá-López
| ONCOLOGY journal Verified
Articles by Daniel Alcalá-López TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i ByAntonio Llombart-Cussac,José Manuel Pérez-García,Elena Lopez-Miranda,Cristina Saavedra,Vicente Carañana,Isabel Blancas,Carmen Hinojo-González,Alfonso Cortes-Salgado,Elena Galve,Rui Rui Zhang,Miguel...
Open in Who Shared View Duplicates (5) Issue with article?
Show More